CoreCap Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.58M Buy
3,816
+293
+8% +$299K 0.13% 161
2026
Q1
$3.24M Sell
3,523
-481
-12% -$488K 0.11% 174
2025
Q4
$4.3M Buy
4,004
+191
+5% +$183K 0.15% 143
2025
Q3
$2.91M Sell
3,813
-53
-1% -$39.4K 0.11% 189
2025
Q2
$3.01M Sell
3,866
-63
-2% -$49K 0.12% 160
2025
Q1
$3.24M Sell
3,929
-2,829
-42% -$2.35M 0.14% 137
2024
Q4
$5.22M Buy
6,758
+355
+6% +$294K 0.24% 73
2024
Q3
$5.67M Buy
+6,403
New +$5.76M 0.27% 69
2024
Q2
Sell
-6,207
Closed -$4.83M 2179
2024
Q1
$4.83M Buy
6,207
+343
+6% +$244K 0.26% 69
2023
Q4
$3.42M Buy
5,864
+88
+2% +$51.4K 0.22% 92
2023
Q3
$3.1M Buy
5,776
+2,705
+88% +$1.39M 0.22% 90
2023
Q2
$1.44M Buy
+3,071
New +$1.29M 0.1% 194
2022
Q4
$2.83M Buy
7,737
+3,270
+73% +$1.16M 0.2% 87
2022
Q3
$1.44M Buy
4,467
+2,104
+89% +$667K 0.12% 151
2022
Q2
$766K Sell
2,363
-104
-4% -$31.2K 0.06% 254
2022
Q1
$706K Sell
2,467
-25
-1% -$6.43K 0.05% 282
2021
Q4
$688K Buy
+2,492
New +$632K 0.05% 303

Other funds holding LLY

CoreCap Advisors's LLY Position: Q2 2026 in Review

CoreCap Advisors increased its Eli Lilly (LLY) stake by 8.3% in Q2 2026, buying an estimated $299K and bringing the position to 3,816 shares worth $4.58M. The position accounts for 0.13% of the portfolio, ranked #161.

CoreCap Advisors first reported a position in LLY in Q4 2021 and has held it in 17 quarters since. The position peaked at $5.67M in Q3 2024. 1,325 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • CoreCap Advisors held 3,816 shares of Eli Lilly worth $4.58M as of Q2 2026.
  • CoreCap Advisors bought 293 Eli Lilly shares in Q2 2026, an estimated $299K.
  • Eli Lilly made up 0.13% of CoreCap Advisors's portfolio in Q2 2026, its #161 holding.
  • CoreCap Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 17 quarters since.
  • CoreCap Advisors's Eli Lilly position peaked at $5.67M in Q3 2024.
  • 1,325 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.